Tempus AI, Inc. (NASDAQ: TEM) operates at the highly specialized confluence of advanced genomic diagnostic sequencing and hyperscale, artificial intelligence-driven data analytics. As the global healthcare ecosystem accelerates its transition toward precision medicine, Tempus has successfully orchestrated a dual-vector revenue model designed to capitalize on the digitization of human biology. The foundational vector relies on a high-volume diagnostics business encompassing oncology, pharmacogenomics, and hereditary testing. This diagnostic engine inherently functions as a data acquisition mechanism, feeding a proprietary, multimodal database that currently exceeds 450 petabytes of paired clinical, molecular, and imaging data.1 This repository is subsequently deployed in the company's second vector: licensing de-identified data to top-tier biophar ...